Advertisement


Everett E. Vokes, MD, on Controversies in Stage IIIA Disease

2015 IASLC World Conference on Lung Cancer

Advertisement

Everett E. Vokes, MD, of the University of Chicago, summarizes expert views on treating stage IIIA disease: decision-making in selecting patients for surgery; multiple-modality choices; and using induction chemotherapy (Abstract ED10).



Related Videos

Lung Cancer

James R. Jett, MD, on Screening With Early CDT and CT

James R. Jett, MD, of National Jewish Health, discusses his study of the early CDT-Lung biomarker. His hypothesis: When used in combination with low-dose CT in screening of a high-risk population, this biomarker would increase the detection of early-stage lung cancer (Abstract MINI 12.11).

Lung Cancer

William D. Travis, MD, on Pathology and Genetics of Lung Tumors: 2015 WHO Classification

William D. Travis, MD, of Memorial Sloan Kettering Cancer Center, gives an update on the WHO classification, which is crucial for optimal personalized treatment of lung cancer patients (Abstract PLEN02.01).

Lung Cancer

Nagashree Seetharamu, MD, on Anti-Glycan Antibody Profiling in De Novo Stage IV Non Small Cell Lung Cancer

Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).

Lung Cancer

Howard Jack West, MD, on New Kinase Targets for Treating Advanced NSCLC

Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of sensitivity to afatinib or neratinib (Abstracts ORAL 3.01, 3.02, and 3.03).

Lung Cancer

Ugo Pastorino, MD, on Reducing Lung Cancer Mortality

Ugo Pastorino, MD, of the Istituto Nazionale dei Tumori Foundation, discusses his study, which showed that stopping smoking before or during low-dose computed tomography screening reduced overall mortality by more than 25%, a benefit that is three- to fivefold greater than this type of screening (Abstract PLEN04.07).

Advertisement

Advertisement




Advertisement